Various antibody therapeutics has been developed for the treatment and suppression of the 2019 outbreak of novel coronavirus（SARS-CoV-2）infection. A major limitation in the development of SARS-CoV-2 neutralizing antibodies is the occurrence and spread of escape variants that have mutations in the spike glycoprotein. The coronaviruses are carried by various wild animals, domestic animals, and pets, and there have been cases of Severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus transmission from animals to people, resulting in a large spread of infection in people. There is also a possibility that cross-species transmission of SARS-CoV-2 may occur in the future. Considering these factors, the development of antibody therapeutics with broad cross-reactivity against SARS-CoV-2 variants and other coronaviruses is required.Alternate :抄録2019年に発生した新型コロナウイルス（SARS-CoV-2）感染症の治療や発症抑制のためにさまざまな抗体医薬の開発が進められている。SARS-CoV-2中和抗体の開発で大きな障壁となるのが、スパイク糖タンパク質に変異をもつ変異株の発生と感染拡大である。またコロナウイルスは多くの野生動物や家畜、愛玩動物が保有しており、これまでにも重篤呼吸器症候群コロナウイルスや中東呼吸器症候群コロナウイルスが動物からヒトへ伝播して大きく感染が広がったケースがある。SARS-CoV-2についても動物が起源であると考えられており、今後も種を越えた伝播が発生する可能性が考えられる。これらを踏まえて、SARS-CoV-2変異株や類縁コロナウイルスに対する交差反応性に優れた抗体医薬の開発が求められる。
Various antibody therapeutics has been developed for the treatment and suppression of the 2019 outbreak of novel coronavirus（SARS-CoV-2）infection。A major limitation in the development of SARS-CoV-2neutralizing antibodies is the occurrence and spread of escape variants that have mutations in the spike glycoprotein。The coronaviruses are carried by various wild animals，domestic animals，and pets，and there have been cases of Severe acute respiratory syndrome coronavirusand Middle East respiratory syndrome coronavirustransmission from animals to people，resulting in a large spread of infection ople。There is also a possibility that cross-species transmission of SARS-CoV-2may occur in the future。Considering these factors，the development of antibody therapeutics with broad cross-reactivity against SARS-CoV-2variants and other coronaviruses is required。Alternate:为了治疗和抑制2019年发生的新型冠状病毒（SARS-COV-2）感染症，正在开发各种抗体医药。在SARS-CoV-2中和抗体的开发中，成为大障碍的是具有尖峰糖蛋白变异的变异株的发生和感染扩大。另外，冠状病毒由很多野生动物、家畜、玩赏动物拥有，至今为止也有严重呼吸综合征冠状病毒和中东呼吸综合征冠状病毒从动物传播到人类，感染扩大的情况。关于SARS-CoV-2，动物也被认为是起源，今后也有可能发生跨物种传播。在此基础上，需要开发对SARS-COV-2变异株和有关冠状病毒的交叉反应性优良的抗体医药。
{"title":"Development of broadly reactive antibody therapeutics for SARS-CoV-2","authors":"Saya Moriyama","doi":"10.2745/dds.37.388","DOIUrl":"https://doi.org/10.2745/dds.37.388","url":null,"abstract":"Various antibody therapeutics has been developed for the treatment and suppression of the 2019 outbreak of novel coronavirus（SARS-CoV-2）infection. A major limitation in the development of SARS-CoV-2 neutralizing antibodies is the occurrence and spread of escape variants that have mutations in the spike glycoprotein. The coronaviruses are carried by various wild animals, domestic animals, and pets, and there have been cases of Severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus transmission from animals to people, resulting in a large spread of infection in people. There is also a possibility that cross-species transmission of SARS-CoV-2 may occur in the future. Considering these factors, the development of antibody therapeutics with broad cross-reactivity against SARS-CoV-2 variants and other coronaviruses is required.Alternate :抄録2019年に発生した新型コロナウイルス（SARS-CoV-2）感染症の治療や発症抑制のためにさまざまな抗体医薬の開発が進められている。SARS-CoV-2中和抗体の開発で大きな障壁となるのが、スパイク糖タンパク質に変異をもつ変異株の発生と感染拡大である。またコロナウイルスは多くの野生動物や家畜、愛玩動物が保有しており、これまでにも重篤呼吸器症候群コロナウイルスや中東呼吸器症候群コロナウイルスが動物からヒトへ伝播して大きく感染が広がったケースがある。SARS-CoV-2についても動物が起源であると考えられており、今後も種を越えた伝播が発生する可能性が考えられる。これらを踏まえて、SARS-CoV-2変異株や類縁コロナウイルスに対する交差反応性に優れた抗体医薬の開発が求められる。","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45625062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The development of DDS technology has contributed critically to the unprecedentedly rapid requirement for vaccines against COVID-19. LNP-based mRNA vaccines represent a subset of emerging DDS technology. Despite the groundbreaking nature of these vaccines, they are yet to be perfected and as such, new technologies are being developed to optimize these vaccines. This review will focus on exploring one of the modalities of recombinant protein vaccines and will introduce various findings on the enhancement of vaccine efficacy using antigen modification technologies, including VLPs and Fc-fusion proteins, and adjuvant improvements.Alternate :抄録COVID-19に対してかつてない速度でワクチンが普及した背景には、DDS技術の発展が必要不可欠であった。特に、mRNAワクチンにおける脂質ナノ粒子（LNP）の開発は、まさにDDS技術の結集といえよう。一方で、mRNAワクチンを含め、現状のさまざまなワクチンは多くの課題を有しており、より効果的かつ安全なワクチン開発に資する基盤技術の確立が世界的に待望されている。本稿では、ワクチンモダリティの1つである組換えタンパク質ワクチンに焦点を絞り、抗原改変技術からアジュバントの改良に至るまで、ワクチン開発基盤技術の最新知見について紹介する。
The development of DDS technology has contributed critically to The unprecedentedly rapidrequirement for vaccines against coviment -19. LNP-based mRNA vaccines represent a subset of emergingDDS technology. Despite the groundbreaking nature of these vaccines，they are yet to be perfected and as such，新技术are being developed to optimize these vaccines. This review will focus on exploringone of the modalities of recombinant protein vaccines and will introduce various findings on thevaccine efficacy using antigen modification technologies，including VLPs and Fc-fusion proteins，与adjuvant improvements.Alternate:摘要针对COVID-19疫苗以前所未有的速度普及的背景下，DDS技术的发展是必不可少的。特别是mRNA疫苗中的脂质纳米粒子(LNP)的开发，可以说是DDS技术的结集。另一方面，包括mRNA疫苗在内，目前各种各样的疫苗都面临着很多问题，世界各国都期待着能够建立更有效、更安全的疫苗开发基础技术。本文聚焦于疫苗模态之一的重组蛋白疫苗，从抗原改变技术到附加组件的改良，介绍疫苗开发基础技术的最新知识。
{"title":"Current Status and Prospects of Vaccines based on DDS Technology","authors":"Atsushi Kawai, Toshiro Hirai, Yasushi Yoshioka","doi":"10.2745/dds.37.402","DOIUrl":"https://doi.org/10.2745/dds.37.402","url":null,"abstract":"The development of DDS technology has contributed critically to the unprecedentedly rapid requirement for vaccines against COVID-19. LNP-based mRNA vaccines represent a subset of emerging DDS technology. Despite the groundbreaking nature of these vaccines, they are yet to be perfected and as such, new technologies are being developed to optimize these vaccines. This review will focus on exploring one of the modalities of recombinant protein vaccines and will introduce various findings on the enhancement of vaccine efficacy using antigen modification technologies, including VLPs and Fc-fusion proteins, and adjuvant improvements.Alternate :抄録COVID-19に対してかつてない速度でワクチンが普及した背景には、DDS技術の発展が必要不可欠であった。特に、mRNAワクチンにおける脂質ナノ粒子（LNP）の開発は、まさにDDS技術の結集といえよう。一方で、mRNAワクチンを含め、現状のさまざまなワクチンは多くの課題を有しており、より効果的かつ安全なワクチン開発に資する基盤技術の確立が世界的に待望されている。本稿では、ワクチンモダリティの1つである組換えタンパク質ワクチンに焦点を絞り、抗原改変技術からアジュバントの改良に至るまで、ワクチン開発基盤技術の最新知見について紹介する。","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47316177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Development of mucosal vaccine based on DDS","authors":"Koji Hosomi, J. Kunisawa","doi":"10.2745/dds.37.412","DOIUrl":"https://doi.org/10.2745/dds.37.412","url":null,"abstract":"","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47545722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Easy to take formulation for children and the elderly patients","authors":"T. Harada","doi":"10.2745/dds.37.284","DOIUrl":"https://doi.org/10.2745/dds.37.284","url":null,"abstract":"","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48459574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluation of intestinal absorption of drugs and drug-induced intestinal toxicity with differentiated human absorptive epithelial cells derived from human crypts","authors":"K. Maeda","doi":"10.2745/dds.37.303","DOIUrl":"https://doi.org/10.2745/dds.37.303","url":null,"abstract":"","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47647329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Booster of the development of personalized therapy: Manufacture of tailored medicine using 3D printing technology","authors":"T. Tagami, Koki Ogawa, T. Ozeki","doi":"10.2745/dds.37.294","DOIUrl":"https://doi.org/10.2745/dds.37.294","url":null,"abstract":"","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41533091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prospects for quantitative prediction of oral drug absorption in individual patients","authors":"Y. Shirasaka","doi":"10.2745/dds.37.321","DOIUrl":"https://doi.org/10.2745/dds.37.321","url":null,"abstract":"","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41847072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：